DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision,” “we,” “our,” “us” or the “Company”) today reported its financial results for the third quarter ended September 27, 2025. “Our strong performance this quarter…
Author: Business Wire
Broadwood Partners Condemns Alcon’s Fallacious Attacks on STAAR Surgical and Its Prospects
NEW YORK–(BUSINESS WIRE)–Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on the investor presentation issued by Alcon Inc. (“Alcon”) (NYSE: ALC) regarding its proposed acquisition of STAAR Surgical Company (“STAAR” o…
Sydnexis Announces Topline Pivotal Data from Phase 3 STAR Trial of SYD-101 for Patients with Pediatric Progressive Myopia Presented at AMCP Nexus 2025
DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis Announces Topline Pivotal Data from Phase 3 STAR Trial of SYD-101 for Patients with Pediatric Progressive Myopia Presented at AMCP Nexus 2025
Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
GENEVA–(BUSINESS WIRE)–Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
Bausch + Lomb to Hold Investor Day on Nov. 13
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will hold an investor day on Thursday, Nov. 13, 2025, at the New York Stock Exchan…
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced the successf…
Glaukos Announces Participation in Upcoming Investor Conferences
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that i…
HTC and IngenioSpec Settled ITC Dispute on Electronic Eyewear Products
WACO, Texas–(BUSINESS WIRE)– #audio–IngenioSpec Resolves Patent Dispute with HTC on Electronic Eyewear Technology.
20/20 Onsite Tops 20+ CNS Trials, Driving Quality Ocular Endpoint Protection at Scale
BOSTON–(BUSINESS WIRE)– #ClinicalTrials–20/20 Onsite tops 20 CNS trials, delivering quality ocular endpoint protection via point-of-need mobile vision clinics. 95+ NPS & 100% timelines met.
Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon
HONG KONG–(BUSINESS WIRE)–Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ:STAA), today rel…
Advancing Sight Network Receives $25,000 Grant from EyeSight Foundation of Alabama to Pursue Cures for Vision Loss
BIRMINGHAM, Ala.–(BUSINESS WIRE)–Advancing Sight Network, an Alabama-based nonprofit dedicated to preserving and restoring eyesight, has received a $25,000 grant from the EyeSight Foundation of Alabama and the Community Foundation of Greater Birmingh…
GenSight Biologics Announces Regulatory Authorizations for Individual Patient Expanded Access Treatment with GS010/LUMEVOQ® in the US
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Samenvatting: Samsung Bioepis gaat BYOOVIZ® (ranibizumab) vanaf januari 2026 in Europa op de markt brengen
INCHEON, Korea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. heeft vandaag bekendgemaakt dat het bedrijf een overeenkomst voor de aankoop van activa (APA) heeft gesloten met Biogen met betrekking tot twee oogheelkundige activa van Samsung Bioepis: BYOOVI…
Samsung Bioepis commercialisera BYOOVIZ® (ranibizumab) en Europe à partir de janvier 2026
INCHEON, Corée–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. a annoncé aujourd’hui avoir conclu un accord d’achat d’actifs (APA) avec Biogen concernant deux actifs ophtalmologiques de Samsung Bioepis : BYOOVIZ® (ranibizumab), un biosimilaire référencé Lu…
Riassunto: Samsung Bioepis commercializzerà BYOOVIZ® (ranibizumab) in Europa a partire dal mese di gennaio 2026
INCHEON, Corea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. oggi ha annunciato di aver sottoscritto un accordo di acquisto di asset (APA) da Biogen relativo a due asset oftalmici di Samsung Bioepis in Europa: BYOOVIZ® (ranibizumab), un biosimilare il cu…
Resumen: Samsung Bioepis comercializará BYOOVIZ® (ranibizumab) en Europa a partir de enero de 2026
INCHEON, Corea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. ha anunciado hoy que la empresa ha firmado un acuerdo de compra de activos (APA) con Biogen para la comercialización de dos activos oftalmológicos de Samsung Bioepis: BYOOVIZ® (ranibizumab), un…
Samsung Bioepis wird BYOOVIZ® (Ranibizumab) ab Januar 2026 in Europa vermarkten
INCHEON, Korea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. gab heute bekannt, dass das Unternehmen mit Biogen einen Kaufvertrag (Asset Purchase Agreement, APA) über zwei Augenheilkunde-Produkte von Samsung Bioepis abgeschlossen hat: BYOOVIZ® (Ranibizum…
Glaukos Announces Third Quarter 2025 Financial Results
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced finan…
Bausch + Lomb Announces Third-Quarter 2025 Results
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2025 financial results. “We’re delivering on the…
Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 2026
INCHEON, Korea–(BUSINESS WIRE)– #BYOOVIZ–Samsung Bioepis Co., Ltd. announced today that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis’ two ophthalmology assets: BYOOVIZ® (ranibizumab), a biosimi…